Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

News
1

https://www.businesswire.com/news/home/20251003096029/en/Alto-Neuroscience-Receives-FDA-Fast-Track-Designation-for-ALTO-101-for-the-Treatment-of-Cognitive-Impairment-Associated-with-Schizophrenia

ALTO-101, a novel PDE4 inhibitor, has demonstrated pro-cognitive effects in healthy volunteers –

Designation highlights the significant unmet need for new treatments for cognitive impairment associated with schizophrenia (CIAS)

3 Likes
2

Thanks for this very good news ! Fast-track designation is quite something !

1 Like